HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice.
Zamaneh HajikhezriFarzin RoohvandMonireh MalekiShohreh ShahmahmoodiAli Akbar AmirzargarAbolfazl KeshavarzNegar SeyedMohammad FarahmandKatayoun Samimi-RadPublished in: Vaccines (2021)
Feeble cellular responses induced by T cell-based vaccines are a major challenge for the development of an effective vaccine against Hepatitis C virus (HCV) infection. To address this challenge, the potential of N-terminal fragment of gp96 heat shock protein (rNT (gp96) as an adjuvant was evaluated and compared to that of the CpG (as a recognized Th1-type adjuvant) in the formulation of HCV core/NS3 antigens in three immunization strategies of protein/protein, DNA/DNA, and DNA/protein. Immunized mice were evaluated for elicited immune responses in week 3 (W3) and 11 post-immunizations. Our results demonstrated that the protein (subunit) vaccine formulated with rNT (gp96) in protein/protein strategy (core/NS3 + gp96) was significantly more efficient than CpG oligodeoxynucleotides (CpG ODN) formulation and all other immunization strategies in the induction of Th1-type cytokines. This group of mice (core/NS3 + gp96) also elicited a high level of anti-Core-NS3 total immunoglobulin G (IgG) with dominant IgG2a isotype at W3. Thus, the co-administration of recombinant NT (gp96) protein with rHCV proteins might be a promising approach in the formulation of HCV subunit vaccine candidates for induction of high levels of Th1 cytokines and humoral responses.
Keyphrases
- protein protein
- hepatitis c virus
- small molecule
- heat shock protein
- heat shock
- immune response
- dengue virus
- human immunodeficiency virus
- drug delivery
- cell free
- circulating tumor
- binding protein
- early stage
- single molecule
- randomized controlled trial
- amino acid
- risk assessment
- climate change
- oxidative stress
- hiv infected
- endothelial cells